A 503B outsourcing facility's FDA registration carries a recurring compliance calendar that runs for as long as the facility wants to keep compounding without patient-specific prescriptions: a biannual product report, an annual registration renewal, and prompt notice to FDA of any sale, relocation, or change in the facility's official contact. FDA checks that calendar before it checks anything else at the next inspection. Investigators compare the registration and reporting history against what they find on site, and a gap in either becomes the first finding of the visit, sometimes for a filing that was due a year earlier.
The Biannual Product Report
Registered outsourcing facilities report the drug products they compounded twice a year, in June and December, in addition to the report due with initial registration. Each report covers the preceding six-month production period, filed electronically in structured product labeling (SPL) format through FDA's CDER Direct system unless FDA has granted a waiver. The obligation does not pause for a quiet production period: a facility that compounded nothing during a given window still files a report reflecting that. Facilities most often miss a cycle after losing the staff member who held the CDER Direct account credentials, or after handing product reporting to a vendor who assumed someone else was filing it.
Annual Registration Renewal
Section 503B registration runs on an annual cycle. Every outsourcing facility must re-register and pay the annual establishment fee during the window FDA opens each year between October 1 and December 31 to remain registered through December 31 of the following year. A facility that misses the window is removed from FDA's list of registered outsourcing facilities on January 1, losing the 503B exemptions its business model depends on until it completes re-registration. The same October-to-December window doubles as an information review: FDA requires every registrant to review its registration details and either certify that nothing has changed or update what has.
Reporting Changes to the Facility and Its Ownership
Federal regulation requires a registered establishment, outsourcing facilities included, to update its FDA registration within 30 calendar days of selling or closing the facility, changing its name or physical address, or changing the official contact FDA has on file (21 CFR 207.29). A sale that changes who owns the facility, a move to a new address, and a new compliance lead who becomes the registered contact each start that 30-day clock on their own, separate from the annual October renewal. FDA's investigators compare the registration record, the ownership, address and contact on file, and the compounded-product history from the last two biannual reports, against what they find on the ground before they open a single batch record.
A registration that lists an address the facility left, or a biannual report that was never filed, turns a routine inspection into one that opens with a discrepancy instead of a tour.
Why Early Legal Counsel Is Critical
It is critical that a compounding pharmacy retain experienced healthcare defense counsel before a registration lapse, a missed product report, or an unreported ownership change surfaces at an FDA inspection, not after. Early legal involvement can confirm which filings are outstanding, correct a registration record before an inspector finds the discrepancy, and preserve the facility's 503B status while a lapsed renewal or an overdue update is being fixed. Delaying legal representation can turn a filing gap that FDA would otherwise treat as an administrative correction into a finding that follows the facility into every later inspection.
How Health Law Alliance Can Help
Health Law Alliance advises 503A and 503B compounding pharmacies nationwide on the recurring FDA obligations that follow registration, alongside the current good manufacturing practice (cGMP) standards that govern day-to-day operations. Our compounding pharmacy defense attorneys draw on the firm's coverage of registering as a 503B outsourcing facility and cGMP expectations for outsourcing facilities to keep a facility's registration, reporting, and manufacturing record current before a gap becomes an inspection finding. Health Law Alliance has represented 2,500+ clients over 25+ years, including outsourcing facilities managing FDA's registration and reporting calendar. If your facility has a reporting gap or an upcoming renewal, contact us for a free, confidential consultation.
